Carl Zeiss ended fiscal year 2010/11 with a clear increase in revenue and earnings over the prior year, achieving 'record figures for almost all performance indicators'.
Business outside Germany accounted for 87% of total revenue. Particularly strong growth was observed in Asia: here, after currency adjustments, the company posted an increase of 12% and generated revenue totalling EUR 626 million (prior year: EUR 542 million). In America the Carl Zeiss Group increased its revenue by 11% to a total of EUR 975 million (prior year: EUR 898 million). The positive trend in the business with cooperation part...
Business outside Germany accounted for 87% of total revenue. Particularly strong growth was observed in Asia: here, after currency adjustments, the company posted an increase of 12% and generated revenue totalling EUR 626 million (prior year: EUR 542 million). In America the Carl Zeiss Group increased its revenue by 11% to a total of EUR 975 million (prior year: EUR 898 million). The positive trend in the business with cooperation partners continued: revenue rose 10% to EUR 1.222 billion (prior year: EUR 1.110 billion). In Europe the technology group generated growth of 9% after currency adjustments. Here, revenue totalled EUR 1.301 billion – including EUR 485 million in Germany (prior year: EUR 1.190 billion, including EUR 415 million in Germany).
At the end of the fiscal year, EBIT lay at EUR 607 million (prior year: EUR 423 million). Earnings before income taxes totalled EUR 569 million (prior year: EUR 324 million). Earnings after income taxes amounted to EUR 386 million (prior year: EUR 208 million).
On 30 September 2011, Carl Zeiss had a global workforce of 24,192 people, including 10,081 at the company's sites in Germany. In addition, the company trained 430 young people in Germany (prior year: 445). The considerable increase in headcount over the prior year was attributable to the full consolidation of eyeglass manufacturer Carl Zeiss Vision (30 September 2010: 12,971 employees, including 8,292 in Germany). The integration of global player Carl Zeiss Vision has led to an increase in the proportion of employees working for the company outside Germany from around 40% to just under 60%. Carl Zeiss created about 1,200 new jobs worldwide during the fiscal year.
Carl Zeiss ensured that the employees benefited from the company's success in fiscal year 2010/11. Full-time employees in Germany received an annual bonus of EUR 2,000 (gross) and profit-participating certificates totalling EUR 360. These certificates are a special form of profit sharing. These non-transferable securities bear interest during their five-year term and are paid out afterwards. Local profit-sharing models exist for employees in Group companies outside Germany.
In fiscal year 2010/11, cash flow before income taxes totalled EUR 668 million, equating to 16% of revenue (prior year: EUR 506 million, or 17% of revenue). Gross liquidity amounted to EUR 847 million. Net liquidity lay at EUR 397 million (prior year: EUR 884 million). On 30 September 2011 equity totalled over EUR one billion. “Despite the full consolidation of the Vision Care business group and the resulting increase in total assets, we achieved a very good equity ratio of 28%,” Thomas Spitzenpfeil, CFO of Carl Zeiss AG, emphasized. “This means that the equity ratio lies within the target range we have set. The company's exceptionally strong net annual income also contributed to this development.”
In fiscal year 2010/11 Carl Zeiss invested EUR 164 million in property, plant and equipment (prior year: EUR 53 million). This investment figure compared to depreciations totalling EUR 122 million (prior year: EUR 96 million). The funds were primarily focused on the expansion and modernization of the global sites, the setup of development centres in Asia, the expansion of sales networks and the creation of new jobs. In the coming years Carl Zeiss will invest EUR 500 million in the expansion of its sites in Germany. “We are modernizing our infrastructure over the long term,” says Kaschke. “The funds are mainly being channelled into the Semiconductor Manufacturing Technology and Medical Technology business groups as well as into the research and development units in order to further increase profitability through new products.”
The product innovation rate continues to lie at a high level: Carl Zeiss generates around half its revenue with products that are less than three years old. In order to further expand its technology leadership in its various areas of business, the company invests in research and development on an ongoing basis. A total of EUR 359 million was invested for this purpose during fiscal year 20010/11 (prior year: EUR 291 million).
“Innovation can be described as the company's DNA. Pushing the boundaries of optics is our passion and our daily work,” Kaschke continued. “This constantly requires a new way of thinking in technology, processes, business models and customer service.” In the semiconductor area, Carl Zeiss has been working on a future-oriented technology for more than 15 years: Extreme Ultraviolet light (EUV), i.e. very shortwave, invisible light, is to be used for the manufacture of microchips in the future. EUV technology will enable an increase in the integration density of chip structures by a factor of ten, therefore providing the computer and communications industries with a key impetus for further innovations. The start of serial production is planned for the next few years. “Carl Zeiss is the right company for a technological revolution of this dimension. We are investing with vision and farsightedness. We have the strength and stamina to work on important innovations over the long term,” said Kaschke.
During fiscal year 2010/11, the Semiconductor Manufacturing Technology business group generated revenue of EUR 1.378 billion (prior year: EUR 1.187 billion), an increase of 16% over last year's very good figure.
The Industrial Metrology business group ended the fiscal year with a growth in revenue of 35% to a total of EUR 394 million (prior year: EUR 292 million).
In fiscal year 2010/11 the Microscopy business group increased its revenue by 7% over the previous year to a total of EUR 423 million (prior year: EUR 397 million).
The Medical Technology business group ended fiscal 2010/11 with revenue of EUR 854 million, corresponding to an increase of 13% over the prior year (prior year: EUR 754 million). The values deviate from the published figures of Carl Zeiss Meditec AG as a result of different consolidation models.
The Vision Care business group generated revenue of EUR 849 million, a slight reduction over the prior year (prior year: EUR 881 million). The Vision Care business group was fully consolidated in fiscal 2010/11. In the prior year the business of Carl Zeiss Vision was valued at equity in the financial statements of the Carl Zeiss Group.
The Consumer Optics/Optronics business group, which combines the company’s business with binoculars, planetariums, camera and cine lenses as well as optronic products, reported revenue totalling EUR 316 million (prior year: EUR 312 million). This corresponds to an increase of 2% over the prior year.
Carl Zeiss does not expect that the growth generated in the fiscal year just ended will continue to the same extent in the current 2011/12 fiscal year. The company anticipates a slight reduction in revenue. “The lack of economic momentum and the rampant uncertainty in the global economy, partly triggered by the problem of national debt, are currently dampening optimism,” Kaschke stated. Nevertheless, Carl Zeiss looks with confidence to the future. The Carl Zeiss Group is convinced that the importance of the Asian and Latin American markets will continue to grow significantly and develop positively over the mid and long terms. With its broad international footprint, balanced portfolio, innovative strength and flexibility, Carl Zeiss is well poised to address this trend. “We have created a very solid foundation to enable us to further pursue our long-term growth path going forward,” Kaschke continued.